Roche lung cancer drug divarasib shows survival gain in trial
Swiss pharmaceutical giant Roche has reported promising results from a late-stage clinical trial of its experimental lung cancer therapy divarasib. Early data from Phase III testing suggest the treatment may extend overall survival in patients with previously treated non-small cell lung cancer, marking a potential advance in KRAS-targeted therapies.
Roche lung cancer drug divarasib has delivered encouraging results in a pivotal Phase III study, with the Swiss drugmaker reporting improved outcomes for patients suffering from advanced non-small cell lung cancer (NSCLC) after prior treatments. The findings were announced by Roche on Thursday, highlighting progress in targeted cancer therapies for KRAS G12C mutation cases.
Clinical trial results in NSCLC treatment
According to data from the KRAScendo 1 study, patients receiving divarasib experienced longer periods without disease progression compared with those treated using existing standard therapies, including sotorasib and adagrasib. Roche also indicated that early analyses point to a possible improvement in overall survival rates, although full survival datasets will be shared at a later scientific conference.
Safety profile and ongoing studies
The company reported no new safety concerns during the Phase III trial, stating that observed side effects remained manageable and reversible. This supports continued development of the drug, which is being evaluated further in additional late-stage clinical programs.
Expanding clinical research pipeline
Roche is currently advancing two complementary studies: KRAScendo 2, which examines divarasib in combination with pembrolizumab as a first-line treatment, and KRAScendo 3, which investigates its use following surgery and chemo-immunotherapy. These trials aim to determine the drug’s effectiveness across different stages of lung cancer treatment pathways.
The results position divarasib as a potential new option in the evolving field of targeted oncology therapies, particularly for patients with limited alternatives in advanced NSCLC.
Comments you share on our site are a valuable resource for other users. Please be respectful of different opinions and other users. Avoid using rude, aggressive, derogatory, or discriminatory language.